Keywords: Pharming, FDA, Angioedema, Rhucin, Scott Henry, Santarus, Roth, BLA Ruconest

FDA turns down 'incomplete' Rhucin dossier

Article | 01 March 2011

Print This

Dutch biotechnology company Pharming and its marketing partner Santarus have suffered a setback in their bid to bring hereditary angioedema ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in